US FDA approves GSK’s AREXVY, the world’s first respiratory …
May 3, 2023 · Respiratory syncytial virus vaccine, adjuvanted, contains a recombinant subunit prefusion RSV F glycoprotein antigen (RSVPreF3) combined with GSK’s proprietary AS01 E …
RSV (Respiratory Syncytial Virus) | GSK US
RSV (respiratory syncytial virus) is a common, contagious respiratory virus that usually causes mild symptoms. 1 RSV can be severe, especially in infants and older adults, and those with …
About GSK’s RSV vaccine
Jun 7, 2024 · In May 2023, the FDA approved GSK’s RSV vaccine for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 …
GSK presents positive data for AREXVY, its respiratory syncytial virus ...
Oct 8, 2024 · AREXVY is a vaccine indicated for active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in: Individuals 60 …
GSK RSV Vaccine Summary | Vaccines & Immunizations | CDC
Jul 5, 2024 · AREXVY is a vaccine indicated for active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV). CDC …
New data for Arexvy, GSK’s respiratory syncytial virus vaccine, …
Oct 24, 2024 · GSK plc (LSE/NYSE: GSK) today announced new preliminary data for Arexvy (respiratory syncytial virus vaccine, recombinant adjuvanted) in adults aged 18-49 at increased …
ACIP Evidence to Recommendations for Use of GSK Adjuvanted …
Sep 5, 2024 · On May 3, 2023, the Food and Drug Administration (FDA) approved GSK RSVPreF3 vaccine (AREXVY) for prevention of lower respiratory tract disease (LRTD) caused …
GSK claims first global approval for an RSV vaccine
3 days ago · The FDA has approved GSK’s Arexvy shot for the prevention of lower respiratory tract disease caused by RSV in individuals 60 years of age and older, shortly after it was …
GSK announces AREXVY, its respiratory syncytial virus (RSV) …
Aug 17, 2023 · AREXVY was approved by the US Food and Drug Administration (FDA) on May 3rd, 2023, for the prevention of lower respiratory tract disease (LRTD) caused by respiratory …
GSK says RSV vaccine shows 94% efficacy in severe disease
Apr 4, 2025 · GSK's vaccine against respiratory syncytial virus (RSV) is one of the top prospects in its pipeline, but also one with considerable competition, so needs strong data to support the …